GlaxoSmithKline Expands Portfolio of Medicines in the U.S. for Patients with Asthma and COPD

January 28, 2015

January 28, 2015- GlaxoSmithKline(GSK) has announced the availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the United States.

Arnuity™ Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid (ICS) medicine for the maintenance treatment of asthma and Incruse® Ellipta® (umeclidinium bromide) is an anticholinergic indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).   

For more information, read the full release here.

Join Us on COPD360social

Sign In to Participate
Or register to become a member